Antepartum or postpartum isoniazid treatment of latent tuberculosis infection

Obstetrics and Gynecology

Volumn 96, Issue 5, 2000, Pages 757-762

  BOGGESS, KIM A ^a   MYERS, EVAN R ^a   HAMILTON, CAROL DUKES ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRIDOXINE;

ARTICLE; CAUSE OF DEATH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEPATITIS; HUMAN; INFECTION PREVENTION; MATERNAL MORTALITY; MODEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; PUERPERAL INFECTION; PUERPERIUM; THORAX RADIOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISONIAZID; MARKOV CHAINS; NORTH CAROLINA; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; TUBERCULOSIS, PULMONARY;

EID: 0033788211     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1016/s0029-7844(00)01039-5     Document Type: Article

References (35)

1. Jereb JA, Kelly GD, Dooley SW Jr, Cauthen GM, Snider DE Jr. Tuberculosis morbidity in the United States: Final data, 1990. MMWR CDC Surveill Summ 1991;40:23-7.
2. Anonymous. Tuberculosis among pregnant women—New York City, 1985-1992. MMWR Morb Mortal Wkly Rep 1993;42:605.
3. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 1997. Accessed 1990 March 30.
4. Zuber PL, McKenna MT, Binkin NJ, Onorato IM, Castro KG. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997;278:304-7.
5. Ferebee S. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1969;17:29-106.
6. Ferebee S. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Resp Dis 1963;88:161-75.
7. Horwitz O, Payne P, Wilbek E. Epidemiological basis of tuberculosis eradication. The isoniazid trial in Greenland. Bull World Health Organ 1966;35:509-29.
8. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30.
9. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-83.
10. United States Preventive Task Forces. Guide to preventive clinical services. 2nd ed. Alexandria, Virginia: International Medical Publishing, 1996.
11. Groth-Petersen E, Gad U, Ostergaard F. Mass chemoprophylaxis of tuberculosis. Am Rev Resp Dis 1960;81:643-52.
12. Ferebee S, Mount F. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Resp Dis 1962;81:490-521.
13. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-64.
14. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: A U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001.
15. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: A review of available information. Am Rev Respir Dis 1992;145:494-7.
16. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.
17. Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989;104:151-5.
18. Bass JB, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359-74.
19. American College of Obstetricians and Gynecologists. Pulmonary disease in pregnancy. ACOG technical bulletin no. 224. Washington DC: American College of Obstetricians and Gynecologists, 1996.
20. Briggs G, Freeman R, Yaffe S, eds. Drugs in pregnancy and lactation. 4th ed. Baltimore: Williams & Wilkins, 1994.
21. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-61.
22. Salpeter EE, Salpeter SR. Mathematical mode for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol 1998;142:398-406.
23. Davidson PT. Managing tuberculosis during pregnancy. Lancet 1995;346:199-200.
24. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989;140:700-5.
25. Bloom BR, Murray CJ. Tuberculosis: Commentary on a reemergent killer. Science 1992;257:1055-64.
26. Haas D, Des Prez R. Mycobacterium tuberculosis. In: Mandell G, Bennett J, Dolin R, eds. Principles and practices of infectious diseases. Vol. 2. New York: Churchill Livingstone, 1995.
27. Anderson R. United States abridged life tables, 1996. Natl Vital Stat Rep. Hyattsville, MD: National Center for Health Statistics, 1996.
28. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford, 1996.
29. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis 1990;142:848-53.
30. Mohle-Boetani JC, Miller B, Halpern M, Trivedi A, Lessler J, Soloman SL, et al. School-based screening for tuberculous infection. A cost-benefit analysis. JAMA 1995;274:613-9.
31. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola RM, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995;155:1595-600.
32. Bureau of Labor Statistics. Consumer price index 1998. Accessed 1998 March 30.
33. Advisory Council for the Elimination of Tuberculosis. Tuberculosis elimination revisited: Obstacles, opportunities, and a renewed commitment. MMWR Morb Mortal Wkly Rep 1999;48:1-13.
34. Londo R, Bjelland T, Girod C, Glasser M. Prenatal and postpartum Pap smears: Do we need both? Fam Pract Res J 1994;14:359-67.
35. Jain A, Higgins R, Boyle M. Management of low-grade squamous intraepithelial lesions during pregnancy. Am J Obstet Gynecol 1997;177:298-302.